表紙
市場調査レポート

癌におけるオーダーメイド医療:医師レベルにおける主な促進因子・課題の評価 (EU5ヶ国)

Personalised Medicines in Oncology: Assessing Key Drivers and Challenges at the Physician Level (EU5)

発行 FirstWord 商品コード 334906
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
癌におけるオーダーメイド医療:医師レベルにおける主な促進因子・課題の評価 (EU5ヶ国) Personalised Medicines in Oncology: Assessing Key Drivers and Challenges at the Physician Level (EU5)
出版日: 2015年05月01日 ページ情報: 英文
概要

当レポートでは、EU5ヶ国 (フランス、ドイツ、スペイン、イタリアおよび英国) の癌専門医150人を対象に実施した調査の結果に基づき、癌専門医が考えるオーダーメイド医療の分野における重要な問題、課題および機会について考察し、癌専門医は将来どのようなオーダーメイド医療の導入を意図しているのか、調査しています。

取り扱う主な質問

  • EU5ヶ国の医師は、認識されたオーダーメイド医療の利用価値をどのようにランク付けするか?
  • EU5ヶ国の医師は、医師・患者にとってのオーダーメイド医療の主要な潜在的メリットをどのようにランク付けするか?
  • 固形腫瘍・血液腫瘍を含む全ての癌タイプの治療にとって、オーダーメイド医療の現在の利用に関するEU5ヶ国の医師の考察は?
  • EU5ヶ国の医師は、アクセス・データの課題をどのようにランク付けするか?
  • もしアクセス・データの課題が最小限だった場合、EU5ヶ国の医師はオーダーメイド医療をどの程度、指示するか?
  • EU5ヶ国の医師は、どのような重要な要因が現在・将来のオーダーメイド医療の効果的な利用を可能にすると考えているか?

主な調査内容

  • EU5ヶ国の癌専門医のオーダーメイド医療の認識に関する考察、患者ケアへの影響、およびオーダーメイド医療の全体的な臨床転帰に対する価値
  • オーダーメイド医療の重要なメリットに関する見解、オーダーメイド医療が革新的な治療へアクセスする方法に関する主な問題
  • 将来のオーダーメイド医療の利用に関する意見、および導入率を下げる可能性がある主な障壁
目次
Product Code: 596200462

Gain exclusive insights on the perceived value and benefits of personalised medicine and on the key challenges and opportunities in relation to implementation from treating oncologists.

Personalised Medicines in Oncology: Assessing Key Drivers and Challenges at the Physician Level (EU5) is based on survey results from 150 oncologists (104 medical oncologists and 46 haematologist-oncologists) in France, Germany, Spain, Italy and the UKand offers insights on what oncologists believe are the critical issues, challenges and opportunities within the personalised medicines space, and how oncologists intend to adopt personalised medicine in the future.

Quantitative Analysis

A great deal of anticipation and expectation surrounds personalised medicine. While there have been some notable successes, the promise of personalised medicine - right medicine, right patient, right time - has failed to materialise in many disease areas where a personalised approach could drive better patient outcomes. Concerns amongst key stakeholder groups remain, particularly in relation to development, access and implementation of personalised healthcare strategies.

This survey provides EU5 physician insights into personalised medicine within the oncology setting. By understanding what oncologists in the major markets in Europe think about the key challenges, opportunities and concerns, companies operating in the oncology market and seeking to leverage personalised medicine for their products can gain a deep understanding of what's needed to drive long-term commercial success.

Gain Answers to Key Questions

  • How do EU5 physicians rank perceived application values of personalised medicine?
  • How do EU5 physicians rank the top potential benefits of personalised medicine for physicians and patients?
  • What are EU5 physician insights on the current usage of personalised medicine for the treatment of all cancer types, including solid and blood tumours?
  • How do EU5 physicians rank access and data challenges?
  • If access and data challenges were minimal - what proportion of EU5 physicians would prescribe personalised medicines?
  • What critical factors do EU5 physicians think enable effective current and future usage of personalised medicine?

Report Features

Filled with charts and up-to-the-minute survey analysis, this report offers:

  • Precise and timely analysis of EU5 oncologist awareness, perception of value, promise and benefits of personalised medicine
  • Data and insight on current usage and access status, and challenges related to personalised medicine access and adoption intention
  • EU5 Oncologist views on the critical enablers and success factors of personalised medicine, as well as anticipated future developments

Top Takeaways

  • Insight on EU5 oncologist awareness of personalised medicine, their impact on patient care and the value of personalised medicines overall clinical outcomes
  • Views on the critical benefits of personalised medicine, and key issues related to how personalised medicine can support access to innovative therapies
  • Opinions on the future use of personalised medicine, and what key barriers are likely to slow adoption rates
Back to Top